Skip to content

Efficacy and safety study of cervical lymphatic -vein bypass surgery in the treatment of Alzheimer's disease

Efficacy and safety study of cervical lymphatic -vein bypass surgery in the treatment of Alzheimer's disease:Randomized controlled clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092047
Enrollment
Unknown
Registered
2024-11-08
Start date
2024-11-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

surgery group:Cervical LVA
control group:Conventional treatment, no change in original medication habits

Sponsors

Dongguan Chashan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Male or female outpatients aged 50-85 years old 2. Meets National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic criteria for AD 3.The estimated survival time is more than 12 months 4.ASA grading criteria for preoperative anesthesia assessment 5. Volunteer to participate in the project and sign an informed consent form with the guardian

Exclusion criteria

Exclusion criteria: 1. History of significant trauma or surgery to the neck that would affect the outcome of this procedure 2. Vascular dementia, central nervous system infections due to AIDS and syphilis, etc., Creutzfeldt-Jakob disease, Huntington's chorea and Parkinson's disease, dementia with Lewy bodies, traumatic brain injury dementia, physicochemical factors such as drug and alcohol intoxication, important somatic illnesses such as hepatic encephalopathy and pulmonary encephalopathy, endocrine system pathology such as subdural hematomas, thyroid disorders, and parathyroid disorders, as well as vitamin deficiencies or any other Dementia of any other cause 3.Presence of severe mental disorders, risk of suicide, inability to cooperate with treatment 4.literacy or insufficient education to complete the scale assessment 5.Unable to tolerate PET-CT or allergic to contrast media 6. Study sponsor or investigator decision to suspend the study

Design outcomes

Primary

MeasureTime frame
PET/CT Standardized Uptake Value Ratio (SUVR);

Secondary

MeasureTime frame
Plasma-associated Alzheimer's marker assay;Mini-Mental State Examination;Montreal Cognitive Assessment;Activity of Daily Living;

Countries

China

Contacts

Public ContactXie Qingping

Dongguan Chashan Hospital

xqp1376@126.com+86 138 0571 1376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026